Development of t-AML Due to Clonal Expansion of the TP53-Mutated Clone. Chemotherapy imposes selection for the TP53 mutated clone leading to a higher representation (middle panel). Additional driver mutations lead to expansion of leukemic clones (right panel). SNVs=single nucleotide variants.Reprinted by permission from Macmillan Publishers Ltd: Nature. 2014 Dec 8. doi: 10.1038/nature13968, copyright 2014.

Development of t-AML Due to Clonal Expansion of the TP53-Mutated Clone. Chemotherapy imposes selection for the TP53 mutated clone leading to a higher representation (middle panel). Additional driver mutations lead to expansion of leukemic clones (right panel). SNVs=single nucleotide variants.Reprinted by permission from Macmillan Publishers Ltd: Nature. 2014 Dec 8. doi: 10.1038/nature13968, copyright 2014.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal